This study is a comparison between Levobupivacaine and Ropivacaine in PNS guided supraclavicular brachial plexus block for upper limb surgeries
Not Applicable
- Conditions
- Health Condition 1: U072- COVID 19 virus not identified
- Registration Number
- CTRI/2023/03/050376
- Lead Sponsor
- Dr. Yashasvini Lawania
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
ASA grades 1 And 2
Scheduled for elective upper limb surgeries under supraclavicular brachial plexus block
Exclusion Criteria
- Patientâ??s refusal
- Age <18yrs and >60yrs.
- ASA grade 3 and more.
- History of serious pulmonary disease, ischemic heart disease, renal/hepaticdysfunction, coronary artery, or cervical spine disease and patients with abnormal coagulation profile.
- Patient with h/o opioid abuse.
- Patients with local skin site infections.
- Patients with hypersensitivity to any of the drugs used.
- Pregnant and lactating mothers.
- Failure of Block
- Restricted neck movement.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the efficacy of 0.5% Levobupivacaine vs 0.75% Ropivacaine in peripheral nerve stimulator guided supraclavicular brachial plexus block in upper limb surgeriesTimepoint: For first 24 hours in 5 mins, 10 mins, 20 mins, 30 mins, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours and 24 hours
- Secondary Outcome Measures
Name Time Method To compare the side effects of 0.5% Levobupivacaine vs 0.75% Ropivacaine in peripheral nerve stimulator guided supraclavicular brachial plexus block for upper limb surgeriesTimepoint: First 24 hours in 5 mins, 10 mins, 15 mins, 20 mins, 30 mins, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours and 24 hours